Things To Do If You’re Not Eligible for a Health Savings Account

HSA eligibility requires enrollment in a high-deductible health plan as of the first of the month and no conflicting coverage (including Medicare or being claimed as a dependent), so those who don’t qualify should consider alternatives. Practical options highlighted include FSAs (pre-tax payroll contributions, employer may contribute, and funds generally don’t roll over; a 2024 BLS survey shows FSA access of 72% for state/local workers and 47% for private-sector workers), employer-funded HRAs (no employee tax deduction), interest-free monthly payment plans from providers, and manufacturer/patient assistance programs to reduce prescription out-of-pocket costs. These measures are presented as tax-efficient or low-cost ways to manage medical spend when an HSA is not available.

Analysis

Market structure: Employers, FSA/HRA administrators and coupon/discount platforms (GoodRx, GDRX) are the primary beneficiaries as workers who miss HSA eligibility still need tax-advantaged or low-cost paths to meds; hospitals and high-deductible plan-focused insurers could see slight downward pressure on out-of-pocket collections. Expect modest revenue reallocation toward third‑party reimbursement and coupon intermediaries over 6–24 months, compressing gross margins for providers who rely on patient pay balances greater than $500 per claim.

Risk assessment: Tail risks include regulatory action (federal curbs on coupon/copay assistance or expanded HSA eligibility) and sudden employer plan redesigns that shift ~10–20% of employees off FSAs/HRAs; these could crystallize within 3–12 months. Hidden dependencies: GoodRx-like players depend on advertising and pharmacy margins, so a downturn in generic pricing or PBM contracting could cut revenues faster than patient take-up trends imply.

Trade implications: Favor small, tactical exposure to GDRX (capture coupon demand) and to benefits administrators/TPAs; reduce durable overweight to large insurers (UNH, CI) by 1–2% due to incremental pricing pressure on patient collections. Use options to express asymmetry: structured call spreads on GDRX for 3–12 month windows and protective puts on insurers to limit downside if reimbursement flows deteriorate.

Contrarian angles: Consensus underestimates fragility of coupon-based revenue if regulators force manufacturer copay consolidation—this makes GDRX a binary risk/reward. Historically (post‑2016 PBM pricing scrutiny) intermediary margins compressed rapidly in 6–9 months; if that repeats, shorting PBM exposure or buying credit protection on weaker provider balances could outperform.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in GDRX via a 6–12 month call spread (cost-limited) targeting +30–60% upside if coupon/ad coupon revenue grows by >10% YoY; cap loss at premium paid.
• Trim 1–2% net exposure to large insurers (UNH, CI) within 30 days and buy 3–6 month 5–10% OTM puts as downside protection against margin pressure from rising in‑network utilization and reduced patient collections.
• Initiate a relative-value pair: long GDRX (1.5% weight) / short UNH (1.5% weight) to capture middle‑man coupon tailwinds vs insurer collection risk, review P&L at 3 months and rebalance if spread moves >15%.
• Add a 0.5–1% position in benefits administrators/TPAs (select BENF/BENFT-like names or ETF exposure to HR tech) for 12–24 months; exit if employer FSA/HRA adoption falls below 40% of workforce in BLS updates.
• Monitor regulatory signals (CMS/FDA/House committee statements) over next 30–90 days as explicit triggers: if legislation targets copay assistance, reduce GDRX exposure by 50% within 5 trading days.